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Abstract
The aims of this study were to assess the plasma concentrations of romifidine in horses after intravenous
injection, to evaluate the red blood cell (RBC) partitioning of the anaesthetic drug, and to improve
knowledge regarding its sedative effect in horses describing the pharmacokinetic model. Eight adult Stan-
dardbred horses received a single bolus of romifidine at a dosage of 100 lg/kg. Blood samples (5 mL)
were collected immediately before romifidine administration (t0), and at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60,
75, 90, 105, 120, 150 and 180 min after injection. A sedation score was recorded at the same time. The
romifidine concentrations in plasma and red blood cells were determined by high performance liquid chro-
matography (HPLC). The plasma and red blood cell concentrations were correlated with the sedation at
each time point. Romifidine produced a satisfactory level of sedation in all animals. The sedation was
detectable in all horses for up to 105 min. All the animals returned to normal without any behavioural
changes at 180 min. The romifidine concentrations in the red blood cells were significantly higher
(P < 0.01) at all time points than those in the plasma. The T1/2b was 148.67  61.59 min and body clear-
ance was 22.55  6.67 mL/kg per min. The results showed that after a single bolus administration of romi-
fidine, a partitioning in the RBCs was detected.
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Introduction
The use of alpha-2 adrenoceptor agonist drugs has
gained wide acceptance in equine veterinary practice
(Marzok et al. 2014). Xylazine, detomidine and romi-
fidine have currently been approved for use in Eur-
ope (Reg. CE N. 1950/2006) and are used for
purposes of sedation, analgesia and premedication
(England & Clarke 1996; Gozalo-Marcilla et al.
2015).
Romifidine [N-(2-bromo-6-fluoro-phenyl)-4,5-
dihydro-1H-imidazol-2-amine mono-hydrochloride,
C9H9BrFN3], is commonly administered intra-
venously to produce sedation and provide analgesia
in horses. The sedative effects reported are
decreased awareness, ptosis of the head, lower lip
and eyelids, ataxia and a wide stance. Similar to
other alpha-2 agonists, the side effects related to the
administration of romifidine are bradycardia,
arrhythmias, decreased cardiac output and increased
systemic vascular resistance, respiratory depression,
transient decreases in arterial partial pressure of oxy-
gen and ataxia (Wojtasiak-Wypart et al. 2012;
Gozalo-Marcilla et al. 2015). When compared with
IV xylazine (1 mg/kg) or detomidine (20 lg/kg),
romifidine at 40 and 80 lg/kg produced less ataxia
and the horses’ heads were held higher; furthermore,
the duration of these effects was longer than the
others. The lack of ataxia with romifidine has made
it very popular for sedating horses in standing
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procedures, and it is also widely used for premedica-
tion prior to induction of anaesthesia in this species
(Marzok et al. 2014).
Romifidine in horses is usually administered
intravenously (IV) at a dosage ranging from 40
to120 lg/kg (Freeman et al. 2002; Figueiredo et al.
2005). Several pharmacodynamic/pharmacokinetic
studies have shown a prolonged sedative effect at
the higher doses and a phase of residual sedation,
detectable for 10 h after drug administration
(Poulsen Nautrup 1988; England et al. 1992; Woj-
tasiak-Wypart et al. 2012).
Romifidine is a lipophilic drug and easily crosses
cell membranes by passive diffusion. In human medi-
cine, several in vitro studies have suggested the abil-
ity of lipophilic drugs to pass the membranes of red
blood cells (RBCs) (Hinderling 1984, 1997; Reichel
et al. 1994). Among the cellular constituents of
blood, RBCs represent the largest population both in
number and cell size, and some authors have sug-
gested their important role in pharmacokinetic/phar-
macodynamic behaviour (Hinderling 1997; Loos
et al. 2003). Pharmacokinetic parameters are usually
determined by analysis of drug concentrations in
plasma rather than whole blood. Parameters deter-
mined using plasma data may be misleading if con-
centrations of drug differ between plasma and RBCs
(Caglar et al. 2015). Red blood cells may uninten-
tionally serve as a natural blood compartment partic-
ipating in biodistribution, pharmacokinetics, slow
release, metabolism and action of different drugs
(Muzykantov 2010).
Previous studies have described the pharmacoki-
netics of ketamine in plasma and in RBCs in cats,
dogs and horses, explaining the great variability in
the response of these species to the same drug
dosage (Roncada et al. 2003, 2005; Sori et al. 2013)
but, to the best of our knowledge, no data have been
reported in horses regarding the concentrations of
romifidine in RBCs after intravenous administration.
The aims of the present study were to assess the
plasma concentrations of romifidine in horses after
intravenous injection and to compare these concen-
trations with those found in RBCs in order to evalu-
ate the RBC partitioning of the alpha-2
adrenoceptor drug.
Materials and Methods
Animals
Eight client-owned Standardbred horses (four males
and four females) 8.5  3.6 (mean value  SD)
years old, weighing 402  32.7 kg admitted to the
Veterinary Teaching Hospital for diagnostic proce-
dure, were enrolled in the study. The owners of the
animals were informed of the purpose of the study.
All owners provided written informed consent prior
to enrolment of the horses. The study was approved
by the Scientific Ethics Committee for Experimenta-
tion on Animals of Alma Mater Studiorum-Univer-
sity of Bologna. The care and handling of the
animals were in accordance with the provisions of
European Economic Community Council Directive
86/609, adopted by the Italian Government (D.L. 27/
01/1992 no. 116).
The study was carried out in September and
October 2012
The animals were housed in stalls of the Veterinary
Teaching Hospital of the Department of Veterinary
Medical Sciences for a 3 days period of acclimatiza-
tion. The animals were fasted for twelve hours
before the moment of sedation but had free access to
drinking water. According to the classification of the
American Society of Anaesthesiology (ASA), based
on their history, physical examination and clinico-
pathological evaluation, (the horses were classified
as ASA I). The range of haematocrit value was 35–
38% (normal range 32–52%).
Three hours prior to the experiment, the horses
were prepared for intravenous injection by shaving the
hair and washing the skin over the left and the right
jugular veins with surgical soap. The areas were then
infiltrated with 1 mL 2% lidocaine (ATI, Bologna,
Italy). In all horses, a 14-gauge catheter (Milacath,
Mila International, USA) was placed into the right
jugular vein for the collection of blood samples, and a
16-gauge catheter (Milacath) was placed into the left
jugular vein for drug administration The catheter were
sutured with silk suture material. Each horse remained
undisturbed in individual boxes, and romifidine
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(Sedivet 1%; Boheringer Ingelheim Vetmedica,
Milan, Italy) was administered intravenously in a sin-
gle bolus to the horses at a dosage of 100 lg/kg.
Blood sample collection
The catheter in the right jugular vein was used for
blood sampling. Blood samples (5 mL) were col-
lected immediately before romifidine administration
(t0), and at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90,
105, 120, 150 and 180 min after injection. All blood
samples were immediately transferred to heparinised
tubes and centrifuged (1200g) for 20 min at room
temperature. After centrifugation, the plasma was
separated from the entire cellular fraction containing
RBCs; both biological matrices were transferred into
separated clean test tubes and frozen at 20°C until
analysis (about 4 weeks).
Sedation score
Before each blood sampling, each horse underwent
measurement of the degree of sedation using a modi-
fied score proposed by Figueiredo et al. (2005) and
summarized in Table 1. All evaluations were carried
out by the same expert anaesthetist (NR).
Analysis of samples
Chemicals
Water, acetonitrile, methanol and diethyl ether
(HPLC-grade) were obtained from Mallinckrodt
Baker (Milan, Italy). Hydrochloric acid (37%) and
sodium hydroxide (analytical reagent grade) were
purchased from Carlo Erba (Milan-Italy).
Since romifidine pure standard was not available,
the registered and commercial preparation Sedivet
(Boehringer Ingelheim Vetmedica, GmbH) was used
as a reference standard, accepting the EU regulation
that, concerning the veterinary medicinal products,
establishes that the maximum acceptable deviation
in the active substance content of the finished pro-
duct shall not exceed  5% (Directive 2001/82/EC,
2001). Sedivet is an aqueous solution containing
romifidine hydrochloride (10 mg/mL). A bottle of
Sedivet was used to administer four horses the
dosage of romifidine (100 lg/kg), and to prepare the
reference and the calibration curves to be used for
the analysis of samples from the same four horses. A
second bottle of Sedivet, from the same batch of
the first, was used to administer the additional four
horses, and to prepare the reference and the calibra-
tion curves to be used for the analysis of samples
from these last four horses.
HPLC instruments and chromatographic conditions
The HPLC system consisted of a Beckman System
Gold equipped with a 507 autosampler fitted with a
50 lL loop, coupled to an ultraviolet (UV)-photo-
diode array Beckman 168 detector and GOLD
release 4.0 software (Beckman Inst. INC). The UV
absorption was measured at full spectrum (200-
300 nm) and at 215 nm. The analyses were carried
Table 1. Description of sedation score
Score Behaviour
0 No sedation (normal frequency and velocity of movement, ear and neck carriage, eye alertness, lip apposition, postural tone,
stance), the head level above the wither
1 Mild sedation (slightly decreased frequency and velocity of movement, lower ear and neck carriage, reduced eye alertness,
appearance of lip separation, slight base-wide stance, slightly relaxed postural tone), the head level at the same level as the wither
2 Moderate sedation (moderately decreased frequency and velocity of movement, obvious ear tip separation, increased base-wide
stance, appearance of crossed legs, buckled knees and/or fetlocks, more relaxed postural tone), the head level lower than the
wither (at the shoulder one)
3 Deep sedation (markedly decreased frequency and velocity of movement, pronounced ear tip separation, markedly lower neck
carriage, greatly reduced eye alertness, extreme lip separation, markedly increased base-wide stance, increased occurrence
and severity of crossed legs, buckled knees and⁄or fetlocks, pronounced loss of postural tone), the head level lower than the
wither (at the carpal level)
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out at room temperature on a Luna C18 column
(particle size: 5 lm, 250 9 4.6 mm, Phenomenex)
protected with a guard column (Phenomenex Secu-
rityGuard 4 9 2.0 mm). The mobile phase, consist-
ing of a mixture methanol-acetonitrile (2.5:1 v/v) and
orthophosphoric acid (0.01 mol/L) (15:85 v/v), was at
0.7 mL/min flow rate. The injection volume was
50 lL and the total run time was 30 min.
Stock and standard solutions
A stock of the standard solution (0.1 mg/mL) was
prepared by diluting the commercial preparation of
romifidine solution (10 mg/mL). The working solu-
tions were prepared by further dilution of stock solu-
tion in H3PO4 0.01 mol/L to analytical concentration
in the range 0.02–2 lg/mL. Both stock and reference
standard solutions were stable for at least 3 months
at 4  2°C. Plasma and RBC calibration samples
were prepared by pipetting suitable amounts of
working solution of the analyte to 1 mL aliquots of
blank pooled plasma or to 1 g aliquots of blank
pooled RBC. Calibrators and QC (quality control)
were prepared fresh for each batch and then treated
exactly as horse’s samples. Final concentrations of
romifidine in the calibration standards were 0.01,
0.02, 0.05, 0.1, 0.2, 0.5, 1, 2 lg/mL and lg/g in plasma
and RBCs respectively, separating the standard cali-
bration for plasma and RBCs.
Sample preparation for plasma analysis
In a 10 mL borosilicate test tube, standard curve
samples spiked with reference standard or unknown
samples were acidified with 2.5 N hydrochloric acid
(100 lL; pH ≤ 3). Seven millilitres of diethyl ether
were added, the tubes were capped and the mixture
was gently stirred using a rotatory shaker for 10 min.
After centrifugation (1200g for 5 min), the organic
phase was discarded, and the aqueous phase was
alkalinised (pH ≥ 12) by adding 100 lL of 5 N
sodium hydroxide. After addition of 7 mL of diethyl
ether, the mixture was gently stirred using a rotatory
shaker for 10 min. The samples were centrifuged
(1200g for 5 min) and the organic layers were trans-
ferred into a new glass tube. This step was repeated
twice and the second organic layer was transferred in
the same glass tube containing the first one. The
diethyl ether was evaporated under vacuum by Uni-
vapo (StepBio, Bologna, Italy). The residues were
reconstituted with 250 lL of H3PO4 0.01 mol/L, and
50 lL were injected into the HPLC system.
Sample preparation for RBC analysis
Since the high viscosity of cellular fraction containing
RBCs, it was difficult to measure 1 ml using a pip-
ette, therefore it has been decided to weigh accu-
rately one gram by means analytical balance
characterized by a precision of 0.02 mg. One gram
of RBCs was diluted with sodium dihydrogen phos-
phate buffer (0.1 mol/L, 5 mL) and homogenized
using an Ultra-Turrax T25 (Janke and Kunkel, Italy).
Aliquots of the homogenate (2 mL) were transferred
to conical glass screw-capped tubes (15 mL), and
400 lL of NaOH (5 N) were added to obtain a
pH > 12. The tubes were briefly vortex-mixed, and
the samples were then extracted by shaking (10 min)
with 8 mL of diethyl ether. After centrifugation
(1200g for 5 min), the organic phase was transferred
to a clean test tube (10 mL) containing 250 lL of
sulphuric acid (0.25 mol/L) and mixed for 10 min.
The organic phase was decanted and discarded, and
the aqueous layer was dried in a rotatory vacuum
bench evaporator (40°C, UNIVAPO, StepBio,
Bologna, Italy). The residue was dissolved using
200 lL of H3PO4 (0.01 mol/L) and injected (50 lL)
into HPLC.
In vitro study
In order to evaluate the concentration of romifidine
in whole blood, in plasma and in red blood cells an
in vitro assay was performed. Four tubes containing
fresh heparinised horse whole blood (4.0 mL each)
were pre-incubated in a shaking water bath for 5 min
at 37  2°C, and spiked with stock solution to obtain
a romifidine concentration of 1 lg/mL. The reaction
was terminated by transferring the tubes from the
shaking bath to ice water bath at 2, 5, 10 and 30 min.
At each time point aliquots of 1.0 mL were with-
drawn from each tube and represent the whole blood
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fraction. The remaining whole blood (3 mL) was
centrifuged (10 min; 1200g) and plasma was sepa-
rated. One gram of corpuscular fraction containing
RBCs was weighted and 1 mL of plasma measured
and transferred in two new glass tubes. Whole blood,
plasma and RBCs samples were kept at 20°C until
analysis.
Method validation
Validation of the analytical procedure for the extrac-
tion and quantification of romifidine was carried out
before analysis of the experimental samples. Drug-
free plasma samples (1 mL) or drug-free cellular
fraction containing RBCs (1 g) were fortified with
romifidine standard reference solutions in order to
prepare calibration curves ranging from 0.01 to 2 lg/
mL (or lg/g for RBCs).
The linearity of the detector response was deter-
mined by the injection of spiked romifidine standards
into blank matrices at different concentrations (0.01–
2 lg/mL, lg/g for RBCs). The calibration curves
were analysed using least square linear regression
analysis, and the regression coefficient (r2) was calcu-
lated.
The concentrations of romifidine in the unknown
samples were calculated from their peak areas using
the slope and the intercept of the calibration curves.
The recovery percentages were determined by
comparing the peak areas obtained from the spiked
plasma samples and spiked cellular fraction contain-
ing RBCs with the peak areas resulting from the ref-
erence standard solutions.
The inter-day precision expressed as the coeffi-
cient of variation percentage (CV%) was checked by
repeating (five times) the analysis of the spiked
plasma (0.5 lg/mL) and cellular fraction containing
RBCs samples (0.5 lg/g).
The limit of detection (LOD) was established by
the Signal-to-Noise ratio at the romifidine retention
time. The LOD was estimated taking into considera-
tion a 1:3 ratio between the baseline noise and the
concentration of the calibration standard. The quan-
tification limit (LOQ) was the lowest concentration
of each calibration curve, and the signal at the LOQ
should be at least 10 times the noise level.
This study was carried out according to ISO
9001:2008 requirements.
Statistical analysis
Plasma and RBC concentrations of romifidine were
reported as mean  standard deviation (SD). The
Wilcoxon test was used to compare the concentra-
tions in the two different compartments (plasma and
RBCs), and the significance level was fixed at
P < 0.05; statistical analysis was carried out using
computer software (Med-Calc 12.7.5, MedCalc Soft-
ware, Acacialaan 22, B-8400 Ostend, Belgium). The
sedation scores (mean  SD), plasma concentrations
and RBC concentrations of romifidine were analysed
using multilevel mixed-effects linear regression anal-
ysis (Med-Calc 12.7.5, MedCalc Software).
All pharmacokinetic parameters were reported as
means  SDs and were determined using computer
software (WinNonlin 6.3; Pharsight Economy
License, Pharsight Corporation, Mountain View,
CA).The pharmacokinetic parameters evaluated
were: A and B (the intercepts of the distribution and
elimination phases), a and b (the rate constants of
the distribution and elimination phases), t1/2a and
t1/2b (the half lives of the distribution and elimination
phases), AUC0?∞ (the area under the curve to infin-
ity), Cl (body clearance), Vdss (volume of distribu-
tion at a steady state), Vc (volume of distribution for
the central compartment), V2 (volume of distribu-
tion for the shallow peripheral compartment), Cmax
(peak drug concentration), and MRT (mean resi-
dence time). t1/2b, was reported as harmonic mean.
The individual plasma concentration-versus-time
curves were fitted and the best compartment model
was determined by application of the Akaike infor-
mation criterion and Schwartz criterion (Schwartz
1978).
Results
Sedation
Romifidine produced a good level of sedation in all
animals as reported in Fig. 1. Sedation in all the
horses was observable for up to 105 min (mean
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sedation score 1). Moreover, three horses at 120 min
and one horse at 150 min were still sedated, and a
sedation score of one was recorded. All the animals
returned to normal without any behavioural changes
at 180 min.
During clinical evaluation, the animals were in the
corner of the stall and, in the first 40 min (mean
sedation score 2.1  0.35), they did not react when
the operator entered the stall. The correlation
between the sedation score with romifidine plasma
RBC concentration highlighted a significant Spear-
man’s coefficient (0.977 and 0.983 respectively) at
each time point (p < 0.01) as show in Fig. 1.
Chromatography
Figure 2 shows a chromatogram of 0.5 ng/mL stan-
dard of romifidine (2-a), of blank RBCs (2-b) and a
sample of RBCs collected after the administration of
romifidine (2-c). Under the chromatographic condi-
tions adopted, the retention time was 6.5 min. The
mean recovery percentages were 92  3.1% for
plasma and 84.6  7.3% for RBCs. The CV% = 4.7
demostrated the high inter-day precision.
The linear regression both in plasma and in RBCs
in the range of 0.01-2 lg/mL or lg/g respectively
showed a high coefficient of correlation (generally
exceeding 0.999 for the standard reference solutions
and 0.99 for the calibration curves). The LOD and
the LOQ were 0.001 lg/mL and 0.01 lg/mL respec-
tively for plasma, and 0.001 lg/g and 0.01 lg/g for
RBCs.
Plasma and RBC concentrations
Romifidine was extracted from plasma and from the
cellular fraction containing RBCs using liquid-liquid
extraction based on the method used for ketamine in
our laboratory (Sori et al. 2013). The molecular
structure of romifidine is different from that of keta-
mine. Both molecules are weakly basic and we veri-
fied that the alkalization allows the extraction with
diethyl ether also for romifidine with a high recovery,
as previously reported.
FIG. 1. Plasma and red blood cell concentrations of romifidine and the sedation scores observed (average values) versus a time profile after
intravenous administration.
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FIG. 2. Chromatogram of 0.5 ng/mL standard of romifidine (a) and of blank RBCs (b), and a sample of RBCs collected after the administration
of romifidine (c). RBC, red blood cell
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As shown in Fig. 1, the romifidine concentrations
in the RBCs were significantly higher (P < 0.01) at
all time points than those evaluated in the plasma.
The results also showed that the release of romifidine
from RBCs to plasma was consistent and continuous
during the entire sedation period (Fig. 1).
In Fig. 3, the diagram shows the fitted regression
line between the concentrations of romifidine in
plasma and its concentrations in RBCs for all the
horses. The estimated regression equation was:
Y ¼ 2:2087þ 1:2732x
with a coefficient of determination (R2) = 0.9990,
an F-ratio = 15844 and a significance level at
P < 0.0001.
Pharmacokinetic parameters
A bicompartmental model was determined to be the
most appropriate for describing the romifidine con-
centration-time profile for plasma. For all horses, the
following equation was appropriate to describe the
romifidine plasma concentrations:
CðtÞ ¼ Aeat þ Bebt
where C(t) is the plasma drug concentration at
time t, e is the base of the natural logarithm, A is the
y-axis intercept, a is the slope for the distribution
phase of the curve, B is the y-axis intercept and b is
the slope for the elimination phase of the curve.
The pharmacokinetic parameters of romifidine in
plasma (means) are summarised in Table 2. As rep-
resented on a log-linear axis (Fig. 1), the initial a-
phase of distribution decreased very rapidly
(a = 0.22  0.08/min) and was characterized by a
short distribution half life (t1/2a=3.55  1.36 min).
The elimination phase (b-phase) was characterized
by a lower slope (b = 0.006  0.0004/min), indicat-
ing a slow decline in blood levels of romifidine as a
result of the elimination processes (metabolism and
excretion). This observation is supported by the t1/2b
and the body clearance values (148.67  61.59 min
and 22.55  6.67 mL/min per kg respectively).
Romifidine was still detected at the last time point of
blood sampling (180 min) in each animal.
In vitro study
Despite differences between the horses, on the basis
of Cmax values of romifidine in plasma (227.37 
FIG. 3. Representative linear relationship between romifidine con-
centrations in the plasma and red blood cells of all the horses
(mean  SD).
Table 2. Pharmacokinetics parameters (obtained from plasma con-
centration) of romifidine administered IV to horses (100 lg/kg) as
single bolus.
Parameters Units Mean SD
A ng/mL 205.21 142.07
B ng/mL 22.16 13.03
a 1/min 0.22 0.08
b 1/min 0.006 0.004
t1/2a min 3.55 1.36
t1/2 b min 119.28 (range 51.6–248.9)
AUC0?∞ min ng/mL 4910.65 1963.68
CL mL/min/kg 22.16 6.67
Vdss mL/kg 3933.15 2002.46
V2 mL/kg 3319.53 1735.39
Cmax ng/mL 227.37 151.53
MRT min 176.75 75.93
A and B: intercepts of the distribution and elimination phases; a
and b: the rate constants of distribution and elimination phases:
t1/2a and t1/2b: half lives of the distribution and elimination phases
(t1/2b is expressed as harmonic mean and range); AUC0?∞: the
area under the curve to infinity; Cl: body clearance; Vdss: volume
of distribution at the steady state; V2: volume of distribution for
the shallow peripheral compartment; Cmax: peak drug concentra-
tion; MRT: mean residence time; SD, standard deviation.
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151.53 ng/mL) and in RBCs (575.47  381.41 ng/
mL), it can assume that RBCs might contain romi-
fidine at about two times the plasma. Moreover,
romifidine concentrates more in the RBC indepen-
dently of the incubation time. The analysis of whole
blood has confirmed this observation; indeed the
concentrations in whole blood are similar to the aver-
age of the plasma and the RBC concentrations. Data
concerning the whole blood concentrations were not
reported because the extraction method applied to
this matrix, despite having been verified on samples
of known concentration, was not validated.
Discussion
In this study, the pharmacokinetics of romifidine and
the partitioning of the drug in the RBCs correlating
the plasma and RBC concentration with the sedation
score were evaluated. The initial hypothesis of romi-
fidine distribution, and partitioning between plasma
and RBCs after intravenous administration to horses
was confirmed. In this study, after IV administration,
the RBC concentrations of romifidine were approxi-
mately two time higher than those detected in
plasma.
The maximal behavioural changes (sedation
scores) were recorded between 2 and 40 min post
injection, and the lowest detectable sedation score
was recorded at 105 min. Our results differ from the
data reported by Wojtasiak-Wypart et al. (2012)
where the authors administered a lower dose of
romifidine (80 lg/kg infused IV over 2 min) and
behavioural changes were noted within 5 min of
romifidine administration that became most promi-
nent between 10 and 60 min and lasted for 120–
150 min. In addition, residual sedation in all horses
up to 120 min was recorded. The author supposed
that these differences could be related to different
dosage and different time of bolus infusion. How-
ever, Hamm et al. (1995) reported long sedation with
a high detomidine dose (40 lg/kg IV) as compared
to 80 lg/kg romifidine IV bolus. Freeman & England
(2000) reported that using romifidine in horses at
two different dosages (80–120 lg/kg IV) reduced the
horse response to auditory and tactile stimulation,
and their degree of ataxia for up to 80 min.
The HPLC method used in this study is specific
and sensitive for studying the disposition kinetics of
romifidine in plasma and the concentration profile in
RBCs. The plasma concentration vs. the time curve
after IV romifidine administration in horses was well
described by a bicompartmental model (Fig. 1). The
same bicompartmental model has been chosen by
other authors in pharmacokinetic studies regarding
romifidine in horses (Hammer 2004; Wojtasiak-
Wypart et al. 2012).
Our results showed a rapid distribution phase (t1/2a
3.55  1.36 min) which was shorter than the value of
romifidine obtained by Wojtasiak-Wypart et al.
(2012), followed by a long elimination half-life
(119.3-range 51.6–248.9 min) similar to the data pre-
viously reported by Wojtasiak-Wypart et al. (2012)
and longer than the elimination half-life described
for detomidine and xylazine in horses (30 and 50 min
respectively) (Garcia-Villar et al. 1981; Grimsrud
et al. 2009).
Our study show that, after IV administration, a
large quantity of drug is detected into the red blood
cells.
The plasma concentration vs. the time curve after
IV romifidine administration in horses was described
by a bicompartmental model (Fig. 1). The same
bicompartmental model has been chosen by other
authors in pharmacokinetic studies regarding romi-
fidine in horses (Hammer 2004; Wojtasiak-Wypart
et al. 2012).
The rapid sequestration of romifidine into RBCs
may also explain some significant pharmacodynamics
effects observed in the study by Wojtasiak-Wypart
et al. (2012) such as the early and rapid decrease in
heart rate and increase in arterial blood pressures,
limited to only 5 min. The partitioning of drugs in
the RBCs was first pointed out by Hinderling (1984,
1997). The RBCs represent the largest cell popula-
tion of the blood. Previous studies have suggested
that RBC partitioning depends, for the most part, on
lipophilicity, molecular size and the chiral character-
istics of the drug (Giebel & Passow 1960; Deuticke
1977). Romifidine has sufficient lipophilicity to pass
through RBC membrane. If the blood vessels are
considered as a “closed system”, then equilibrium
should be reached when the ratio of unbound
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concentrations of the drug in the aqueous phase of
the plasma and RBC cytosol remain constant as has
previously been described for ketamine (Sori et al.
2013). On the contrary, in our study, the concentra-
tion of romifidine was higher in RBCs than in plasma
at the same sampling time points in most horses and
this could be explained by the parallel transport of
the carrier-mediated and the passive diffusion mech-
anisms. Moreover, romifidine, could bind to different
RBC components, such as haemoglobin, protein, the
plasma membrane and enzymes (Hinderling 1984,
1997).The RBC to plasma ratios were constant over
time in the studied horses, independent of the sam-
pling time point for blood collection. This finding
indicates that RBCs do not act as a depot for romi-
fidine in which the drug accumulates over time, as
has been described for other drugs in human medi-
cine, that is, for lometrexol (Synold et al. 1998).
Therefore, it could be more likely a “weak and rever-
sible” binding of romifidine with the membrane of
red blood cells or with molecules inside the red
blood cells.
The drugs in the red blood cells are inactive and
can be released when the plasma concentrations of
the drug decrease; this condition could allow main-
taining the plasma concentration stable for a long
period of time. In our experiment, six out of the eight
horses had romifidine plasma concentrations higher
than 10 ng/mL from 30 to 180 min. The minimum
plasma concentration which produces sedation in
horses is still not clear for all alpha2-agonists but, in
this study, a sedation score of one was recorded with
a plasma concentration of romifidine higher than
10 ng/mL at 105 min.
In conclusion, the results showed that after a single
bolus administration of romifidine, a partitioning in
the RBCs was detected. This finding could explain
the long sedative action of romifidine, observed by
different authors in horses after a single bolus injec-
tion.
Additional in vitro study should be carried out to
improve knowledge regarding the mechanism of the
partitioning of romifidine in RBCs. Additional phar-
macokinetic and pharmacodynamic studies of romi-
fidine should also be conducted in anaemic and
polycythemic horses.
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